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Abstract 14 
The porcine respiratory disease complex greatly affects the health and production of 15 
pigs. While antimicrobial agents are used to treat the respiratory infections caused by 16 
bacterial pathogens, there is no current information on antimicrobial resistance in Australian 17 
pig respiratory bacterial isolates. The aim of this study was to determine the antimicrobial 18 
resistance profiles, by determining the minimum inhibitory concentration of nine 19 
antimicrobial agents for 71 Actinobacillus pleuropneumoniae, 51 Pasteurella multocida and 20 
18 Bordetella bronchiseptica cultured from Australian pigs. The majority of 21 
A. pleuropneumoniae isolates were resistant to erythromycin (89%) and tetracycline (75%). 22 
Resistance to ampicillin (8.5%), penicillin (8.5%) and tilmicosin (25%) was also identified. 23 
The P. multocida isolates exhibited resistance to co-trimoxazole (2%), florfenicol (2%), 24 
ampicillin (4%), penicillin (4%), erythromycin (14%) and tetracycline (28%). While all the 25 
B. bronchiseptica isolates showed resistance to beta-lactams (ampicillin, ceftiofur and 26 
penicillin), some were resistant to erythromycin (94%), florfenicol (6%), tilmicosin (22%) 27 
and tetracycline (39%). The incidence of multiple drug resistance (MDR) varied across the 28 
species – in B. bronchiseptica, 27.8% of resistant isolates showed MDR, while 9.1% of the 29 
resistant isolates in A. pleuropneumoniae, and 4.8% in P. multocida showed MDR. This 30 
study illustrated that Australian pig strains of bacterial respiratory pathogens exhibited low 31 
levels of resistance to antimicrobial agents commonly used in the pig industry. 32 
Keywords: Porcine respiratory disease; antimicrobial susceptibility testing; 33 
antimicrobial resistance 34 
Page 3 of 14
Ac
ce
pte
d M
an
us
cri
pt
3 
 
1. Introduction 35 
The porcine respiratory disease complex (PRDC), one of the most significant problems 36 
affecting health and production in the pig industry worldwide, is described as a multifactorial 37 
pneumonic state resulting from the interaction of bacteria, viruses and stresses caused by 38 
management, environment and genetic conditions (Opriessnig et al., 2011). A range of 39 
bacterial pathogens is associated with the initiation and progress of PRDC, with Mycoplasma 40 
hyopneumoniae, Actinobacillus pleuropneumoniae, Haemophilus parasuis, Pasteurella 41 
multocida and Bordetella bronchiseptica having significant roles (Fablet et al., 2011; 42 
Opriessnig et al., 2011). 43 
The use of antimicrobial agents, beta-lactams (ampicillin, penicillin and 44 
cephalosporins) (except for B. bronchiseptica), co-trimoxazole (sulfonamide and 45 
trimethoprim combination), florfenicol, macrolides (erythromycin, tilmicosin and 46 
tulathromycin) and tetracyclines remains the best treatment option to control PRDC (Karriker 47 
et al., 2013). The usage of antimicrobial agents has the potential to select for antimicrobial 48 
resistance (Barton et al., 2003). Resistance to antimicrobials commonly used to treat PRDC 49 
have been detected previously in porcine respiratory disease pathogens from many countries 50 
(Vicca et al., 2004; de la Fuente et al., 2007; San Millan et al., 2009; Tang et al., 2009; 51 
Chander et al., 2011; Kucerova et al., 2011; Nedbalcová et al., 2013). 52 
In the past, antimicrobial resistance in Australia was reported in A. pleuropneumoniae 53 
(Eaves et al., 1989) and P. multocida (Stephens et al., 1995). However, no information exists 54 
for B. bronchiseptica. Thus, this study aimed to determine the antimicrobial susceptibility of 55 
A. pleuropneumoniae, P. multocida and B. bronchiseptica Australian isolates against 56 
antimicrobial agents used for bacterial respiratory pathogens.  57 
Page 4 of 14
Ac
ce
pte
d M
an
us
cri
pt
4 
 
2. Materials and Methods 58 
The bacterial isolates tested were obtained from Australian pigs in diagnostic disease 59 
investigations and then submitted to the Microbiology Research Group, EcoSciences 60 
Precinct, Department of Agriculture Fisheries and Forestry (DAFF), Queensland, Australia 61 
for confirmatory identification and/or serotyping. A total of 71 A. pleuropneumoniae, 51 62 
P. multocida and 18 B. bronchiseptica isolates collected between the years 2002 to 2013 were 63 
selected from the culture collection of the Microbiology Research Group. All isolates were 64 
diagnostic submissions from Australian pig herds. The A. pleuropneumoniae isolates 65 
represent 19% of the total available culture collection of the Microbiology Research Group 66 
and originated from New South Wales (8 isolates), Queensland (24 isolates), South Australia 67 
(8 isolates), Victoria (24 isolates) and Western Australia (7 isolates). The P. multocida 68 
isolates came from New South Wales (12 isolates), Queensland (22 isolates), South Australia 69 
(3 isolates), Victoria (1 isolate) and Western Australia (13 isolates). The B. bronchiseptica 70 
isolates came from New South Wales (4 isolates), Queensland (13 isolates) and South 71 
Australia (1 isolate). All isolates of P. multocida and B. bronchiseptica existing in the culture 72 
collection were included in this study. With the exception of B. bronchiseptica, all the 73 
isolates had been previously identified by a relevant species specific polymerase chain 74 
reaction (Gram and Ahrens, 1998; Townsend et al., 1998; Miflin and Blackall, 2001). The 75 
B. bronchiseptica isolates had been previously identified by sequencing of the 16S rDNA 76 
gene using a previously described method (Blackall et al., 2001). 77 
Antimicrobial resistance was detected by determination of MIC in duplicate using CLSI 78 
standards and recommendations (CLSI, 2013). The media used were chocolate Mueller 79 
Hinton agar (BD) for A. pleuropneumoniae; and cation adjusted Mueller Hinton broth (BD) 80 
for P. multocida and B. bronchiseptica. The antimicrobials used were ampicillin, ceftiofur, 81 
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co-trimoxazole, florfenicol, erythromycin, penicillin, tetracycline, tilmicosin and 82 
tulathromycin. As per the CLSI (2013), the quality control strains used were 83 
A. pleuropneumoniae (ATCC 27090) and S. aureus (ATCC 29213). 84 
The MIC was defined as the lowest antimicrobial concentration that inhibited bacterial 85 
growth. The interpretation of MIC of each antimicrobial agent against the three bacterial 86 
species was based on the breakpoints provided by the CLSI (2013), where available. As there 87 
are no CLSI interpretative breakpoints for penicillin, the one for ampicillin was used (CLSI, 88 
2013). The breakpoints (shown in Table 1) for some antimicrobial agents were taken from 89 
other published studies and are detailed in the following text. For A. pleuropneumoniae, 90 
breakpoints for erythromycin and co-trimoxazole were the ones used by Archambault et al. 91 
(2012). For P. multocida, the breakpoints used were from the CLSI guidelines (CLSI, 2013) 92 
except for erythromycin (Tang et al., 2009) and co-trimoxazole (Archambault et al., 2012). 93 
The breakpoints used for B. bronchiseptica were the values provided by the CLSI guidelines 94 
(CLSI, 2013) where available while some were taken from the published literature - 95 
erythromycin (Tang et al., 2009) and co-trimoxazole (Archambault et al., 2012). 96 
 97 
3. Results and Discussion 98 
The MIC distribution of 71 A. pleuropneumoniae, 51 P. multocida and 18 99 
B. bronchiseptica isolates, the percentage of resistance in each antimicrobial as well as the 100 
MIC50 and MIC90 are shown in Table 1.The MICs of the reference strains in each test run 101 
were within the CLSI acceptable quality control ranges. All A. pleuropneumoniae were 102 
susceptible to ceftiofur, co-trimoxazole, florfenicol and tulathromycin. Overall, 66 of 71 103 
(93%) of the A. pleuropneumoniae isolates were resistant to one or more antimicrobials, 104 
showing seven antimicrobial resistance patterns. Resistance to ampicillin (8.5%), penicillin 105 
Page 6 of 14
Ac
ce
pte
d M
an
us
cri
pt
6 
 
(8.5%), tilmicosin (25%), tetracycline (75%) and erythromycin (89%) was detected. All 106 
P. multocida isolates were susceptible to ceftiofur, tilmicosin and tulathromycin. Twenty one 107 
(41%) of the isolates exhibited resistance, showing five antimicrobial resistance patterns in 108 
which 2% were resistant to co-trimoxazole, 2% to florfenicol 4% to ampicillin and penicillin, 109 
14% to erythromycin and 28% to tetracycline. All B. bronchiseptica isolates were susceptible 110 
to co-trimoxazole and tulathromycin and resistant to all beta-lactams included in this study. 111 
The obtained MICs showed resistance to florfenicol (6%), tilmicosin (22%), tetracycline 112 
(39%) and erythromycin (94%). The antimicrobial resistance of B. bronchiseptica isolates 113 
demonstrated six patterns. 114 
In examining the results of the current study, there are a number of issues that need to 115 
be considered. Firstly, it is important to understand that the study is based on a collection of 116 
isolates submitted for identification and/or serotyping from across Australia. The collection, 117 
however, cannot be regarded as being representative of the full diversity of these pathogens 118 
present in the Australian pig herd. A much larger study, seen for example in the recent North 119 
American study by Portis et al. (2013), would be required to gain insight into the national 120 
picture in Australia. Secondly, while there is no specific knowledge, it is highly likely that the 121 
isolates used in the current study would have come from pigs exposed to antimicrobial 122 
treatment. Indeed, the antimicrobial agents used in this study are all registered for use in 123 
Australian pigs (https://portal.apvma.gov.au/pubcris). The VetPath program in Europe 124 
(de Jong et al., 2012) is seeking to address this issue by examining isolates obtained prior to 125 
the commencement of any antimicrobial treatment program. Because of these issues (i.e. use 126 
of a collection based on diagnostic submissions with an unknown history of antimicrobial 127 
treatment), no direct comparisons of the levels of resistance found in the current study with 128 
those reported in other studies in other countries will be made. 129 
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There was a lower prevalence of antimicrobial resistance found in P. multocida isolates 130 
compared with the detected resistance in A. pleuropneumoniae (41% showed resistance to at 131 
least one antimicrobial agent compared to 93% of A. pleuropneumoniae isolates). One isolate 132 
showed co-resistance to all antimicrobials except for ceftiofur, tilmicosin and tulathromycin 133 
and gave a high MIC to florfenicol (≥128µg/ml). This particular P. multocida strain and one 134 
B. bronchiseptica are the only isolates amongst all strains in this study to show florfenicol 135 
resistance. Florfenicol resistance has previously been detected in P. multocida isolates in 136 
Germany (Kehrenberg et al., 2005) and in the Czech Republic (Nedbalcová et al., 2013). The 137 
B. bronchiseptica isolates showed resistance to all antimicrobial agents tested except for 138 
tulathromycin and gave high MICs (64 to ≥128 µg/ml) to ceftiofur and penicillin. Resistance 139 
to beta-lactam agents (ampicillin, ceftiofur and penicillin) matches previous reports (Kadlec 140 
et al., 2004; Chander et al., 2011). The beta-lactam resistance of B. bronchiseptica has been 141 
previously detected to be associated with the production of beta lactamase enzymes and 142 
reduced membrane permeability to ceftiofur (Kadlec et al., 2007; Chander et al., 2011). 143 
For the purpose of this study, multidrug-resistance (MDR) was defined as resistance to 144 
three or more antimicrobial classes. The MDR patterns obtained from the tested isolates are 145 
shown in Table 2. In this study, there were two MDR patterns detected in 9.1% (6/66) of the 146 
antimicrobial resistant A. pleuropneumoniae isolates. Only one (1/21) P. multocida isolate 147 
showed MDR, while five B. bronchiseptica isolates (5/18) showed MDR. Interestingly, the 148 
MDR patterns detected differed between Australian bacterial species. The variation across 149 
species might be associated with the resistance mechanisms distinctive to each species which 150 
can be evaluated by genetic characterisation (Kehrenberg et al., 2005; San Millan et al., 2009; 151 
Chander et al., 2011; Archambault et al., 2012). Further investigations are essential to explain 152 
the mechanisms involved in the antimicrobial resistance of Australian species. 153 
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In summary, this study presented data on the antimicrobial resistance profiles of 154 
A. pleuropneumoniae, P. multocida and B. bronchiseptica isolated from Australian pigs. The 155 
study found that Australian strains showed resistance to older (ampicillin, co-trimoxazole, 156 
erythromycin, penicillin and tetracycline) and newer (ceftiofur, florfenicol, tilmicosin and 157 
tulathromycin) generation antimicrobial agents. Antimicrobial susceptibility monitoring 158 
programs of important veterinary pathogens are necessary to provide evidence based 159 
guidance for antimicrobial therapy of bacterial diseases. 160 
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Table 1 
Minimum inhibitory concentration distribution of 71 A. pleuropneumoniae, 51 P. multocida and 18 B. bronchiseptica. 
Antimicrobial agents Number of isolates with MIC (µg/ml) of     % 
and bacterial species ≤0.12 0.25 0.5 1 2 4 8 16 32 64 ≥128 MIC50 MIC90 R 
Ampicillin               
A. pleuropneumoniae  38 27      2 4     ≤ 0.12 0.25 8.5 
P. multocida 38 11 0 0 0 0 1 1    ≤ 0.12 0.25 4 
B. bronchiseptica       5 8 3 2   9 16 100 
Ceftiofur               
A. pleuropneumoniae  71            ≤ 0.12 ≤ 0.12 0 
P. multocida 49 2           ≤ 0.12 ≤ 0.12 0 
B. bronchiseptica           14 4 64 ≥128 100 
Co-trimoxazole               
A. pleuropneumoniae  70 1           ≤ 0.12 ≤ 0.12 0 
P. multocida 49 1     1      ≤ 0.12 ≤ 0.12 2 
B. bronchiseptica 9   9         ≤ 0.12 1 0 
Erythromycin               
A. pleuropneumoniae      8 38 25    8 16 89 
P. multocida   3 3 20 18 7     2 8 14 
B. bronchiseptica      1 15 1 1   8 8 94 
Florfenicol               
A. pleuropneumoniae  3 40 28         0.25 0.5 0 
P. multocida 1  35 13  1     1 0.5 1 2 
B. bronchiseptica     4 13   1   4 4 6 
Penicillin               
A. pleuropneumoniae  7 40 18    1 5      0.25 0.5 8.5 
P. multocida 46 2  1   2     ≤ 0.12 ≤ 0.12 4 
B. bronchiseptica           14 4 64 ≥128 100 
Tetracycline               
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A. pleuropneumoniae   2 16 5 7 8 14 14 5  8 32 75 
P. multocida  1 22 14 5 4 4  1   1 2 28 
B. bronchiseptica   11   7       0.5 2 39 
Tilmicosin               
A. pleuropneumoniae       7 46 16 2  16 32 25 
P. multocida    2 16 17 13 3    4 8 0 
B. bronchiseptica       2 12 3 1  16 32 22 
Tulathromycin               
A. pleuropneumoniae        20 51    32 32 0 
P. multocida 1 22 19 9         0.5 1 0 
B. bronchiseptica     2 9 5 2           1 2 0 
Vertical lines indicate breakpoints for resistance; % R means percentage of resistance 
MIC50, MIC90 - the lowest concentration of antimicrobial agent capable of inhibiting the growth of 50% and 90% of isolates, respectively 
Co-trimoxazole- trimethoprim and sulfamethoxazole in the ratio 1:19; test ranges are expressed as the trimethoprim concentration. 
 242 
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Table 2 
Antimicrobial resistant (AMR) patterns detected in A. pleuropneumoniae, H. parasuis, 
P. multocida and B. bronchiseptica cultured from Australian pigs 
Species AMR pattern  Number of isolates
a
 
A. pleuropneumoniae EryTet 31 
  EryTetTil 13 
  Ery 12 
  
b
AmpEryPenTetTil 4 
  Tet 3 
  
b
AmpEryPenTet 2 
  EryTil 1 
   
P. multocida Tet 13 
 Ery 5 
 EryTet 1 
 AmpPen 1 
 
b
AmpCotriEryFfcPenTet 1 
   
B. bronchiseptica AmpCefEryPen 9 
 AmpCefEryPenTil 3 
 
b
AmpCefEryPenTetTil 2 
 
b
AmpCefEryTetPen 2 
 
b
AmpCefEryFfcPenTetTil 1 
 AmpCefPen 1 
a
Number of isolates showing respective AMR pattern 
b
Multidrug-resistant patterns exhibited by resistant isolates 
Amp- ampicillin, Cef- ceftiofur, Cotri- cotrimoxazole, Ery- erythromycin, Ffc- florfenicol, 
Pen- penicillin, Til- tilmicosin and Tula- tulathromycin  
